{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:57:51Z","timestamp":1791482271737,"version":"4.3.4"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007903","name":"Bloodwise","doi-asserted-by":"publisher","award":["13042"],"award-info":[{"award-number":["13042"]}],"id":[{"id":"10.13039\/501100007903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007903","name":"Bloodwise","doi-asserted-by":"publisher","award":["19004"],"award-info":[{"award-number":["19004"]}],"id":[{"id":"10.13039\/501100007903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011717","name":"Leuka","doi-asserted-by":"publisher","award":["PG17\/002"],"award-info":[{"award-number":["PG17\/002"]}],"id":[{"id":"10.13039\/100011717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Biological Regulation"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jbior.2019.100655","type":"journal-article","created":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T11:30:53Z","timestamp":1568892653000},"page":"100655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Splicing factor mutant myelodysplastic syndromes: Recent advances"],"prefix":"10.1016","volume":"75","author":[{"given":"Andrea","family":"Pellagatti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4330-2928","authenticated-orcid":false,"given":"Jacqueline","family":"Boultwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbior.2019.100655_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jbior.2017.09.008","article-title":"Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches","volume":"67","author":"Armstrong","year":"2018","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.jbior.2019.100655_bib2","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2011.40.7379","article-title":"Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes","volume":"30","author":"Bejar","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbior.2019.100655_bib3","doi-asserted-by":"crossref","first-page":"e87361","DOI":"10.1371\/journal.pone.0087361","article-title":"A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events","volume":"9","author":"Brooks","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jbior.2019.100655_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1083\/jcb.201510032","article-title":"Defective control of pre-messenger RNA splicing in human disease","volume":"212","author":"Chabot","year":"2016","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jbior.2019.100655_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11912-015-0489-2","article-title":"Unraveling myelodysplastic syndromes: current knowledge and future directions","volume":"18","author":"Chamseddine","year":"2016","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.jbior.2019.100655_bib6","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.stemcr.2018.03.020","article-title":"Dissecting the contributions of cooperating gene mutations to cancer phenotypes and drug responses with patient-derived iPSCs","volume":"10","author":"Chang","year":"2018","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.jbior.2019.100655_bib7","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1038\/sj.onc.1203812","article-title":"Activation of the NF-kappaB pathway by caspase 8 and its homologs","volume":"19","author":"Chaudhary","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.jbior.2019.100655_bib8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.molcel.2017.12.029","article-title":"The augmented R-loop is a unifying mechanism for myelodysplastic syndromes induced by high-risk splicing factor mutations","volume":"69","author":"Chen","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jbior.2019.100655_bib9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s11899-015-0269-y","article-title":"Incidence and burden of the myelodysplastic syndromes","volume":"10","author":"Cogle","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.jbior.2019.100655_bib10","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ccell.2015.04.007","article-title":"Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome","volume":"27","author":"Colla","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbior.2019.100655_bib11","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.molcel.2019.01.024","article-title":"R-loops as cellular regulators and genomic threats","volume":"73","author":"Crossley","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jbior.2019.100655_bib12","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1182\/blood-2011-12-400994","article-title":"Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes","volume":"119","author":"Damm","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100655_bib13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.mcna.2016.09.006","article-title":"Myelodysplastic syndromes: updates and nuances","volume":"101","author":"Dao","year":"2017","journal-title":"Med. Clin. N. Am."},{"key":"10.1016\/j.jbior.2019.100655_bib14","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1101\/gad.1973010","article-title":"Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged","volume":"24","author":"David","year":"2010","journal-title":"Genes Dev."},{"key":"10.1016\/j.jbior.2019.100655_bib15","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"de Witte","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100655_bib16","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/leu.2014.331","article-title":"Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells","volume":"29","author":"Dolatshad","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jbior.2019.100655_bib17","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1038\/leu.2016.149","article-title":"Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes","volume":"30","author":"Dolatshad","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jbior.2019.100655_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.exphem.2016.10.008","article-title":"Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies","volume":"46","author":"Dwivedi","year":"2017","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.jbior.2019.100655_bib19","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1158\/1078-0432.CCR-13-0485","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors","volume":"19","author":"Eskens","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbior.2019.100655_bib20","doi-asserted-by":"crossref","first-page":"e1006384","DOI":"10.1371\/journal.pgen.1006384","article-title":"Wild-Type U2AF1 antagonizes the splicing program characteristic of U2AF1-mutant tumors and is required for cell survival","volume":"12","author":"Fei","year":"2016","journal-title":"PLoS Genet."},{"key":"10.1016\/j.jbior.2019.100655_bib21","doi-asserted-by":"crossref","first-page":"E10437","DOI":"10.1073\/pnas.1812669115","article-title":"Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene U2af1","volume":"115","author":"Fei","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbior.2019.100655_bib22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ccell.2019.07.003","article-title":"Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation","volume":"36","author":"Fong","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbior.2019.100655_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/ng.1031","article-title":"Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes","volume":"44","author":"Graubert","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jbior.2019.100655_bib24","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100655_bib25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jbior.2019.100655_bib26","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s10637-013-0046-5","article-title":"A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors","volume":"32","author":"Hong","year":"2014","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.jbior.2019.100655_bib27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1182\/blood.2018884338","article-title":"Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes","volume":"134","author":"Hsu","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100655_bib28","doi-asserted-by":"crossref","first-page":"10838","DOI":"10.1074\/jbc.275.15.10838","article-title":"Activation of NF-kappaB by FADD, casper, and caspase-8","volume":"275","author":"Hu","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbior.2019.100655_bib29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1101\/gr.181016.114","article-title":"U2AF1 mutations alter splice site recognition in hematological malignancies","volume":"25","author":"Ilagan","year":"2015","journal-title":"Genome Res."},{"key":"10.1016\/j.jbior.2019.100655_bib30","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1101\/gad.278424.116","article-title":"Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis","volume":"30","author":"Inoue","year":"2016","journal-title":"Genes Dev."},{"key":"10.1016\/j.jbior.2019.100655_bib31","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00439-017-1791-x","article-title":"Intron retention as a component of regulated gene expression programs","volume":"136","author":"Jacob","year":"2017","journal-title":"Hum. Genet."},{"key":"10.1016\/j.jbior.2019.100655_bib32","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2017-02-692715","article-title":"How do messenger RNA splicing alterations drive myelodysplasia?","volume":"129","author":"Joshi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100655_bib33","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","article-title":"SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition","volume":"27","author":"Kim","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbior.2019.100655_bib34","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1182\/blood-2017-01-762393","article-title":"Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice","volume":"131","author":"Kon","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100655_bib35","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/nm.4165","article-title":"Therapeutic targeting of splicing in cancer","volume":"22","author":"Lee","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.jbior.2019.100655_bib36","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/nm.4097","article-title":"Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins","volume":"22","author":"Lee","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.jbior.2019.100655_bib37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccell.2018.07.003","article-title":"Synthetic lethal and convergent biological effects of cancer-associated spliceosomal gene mutations","volume":"34","author":"Lee","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbior.2019.100655_bib38","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.cell.2005.06.008","article-title":"Inactivation of the SR protein splicing factor ASF\/SF2 results in genomic instability","volume":"122","author":"Li","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.jbior.2019.100655_bib39","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1261\/rna.734407","article-title":"The RNA binding protein RNPS1 alleviates ASF\/SF2 depletion-induced genomic instability","volume":"13","author":"Li","year":"2007","journal-title":"RNA"},{"key":"10.1016\/j.jbior.2019.100655_bib40","doi-asserted-by":"crossref","first-page":"6042","DOI":"10.1038\/ncomms7042","article-title":"Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome","volume":"6","author":"Madan","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbior.2019.100655_bib41","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/blood-2011-12-399774","article-title":"Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis","volume":"119","author":"Makishima","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100655_bib42","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ng.3742","article-title":"Dynamics of clonal evolution in myelodysplastic syndromes","volume":"49","author":"Makishima","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jbior.2019.100655_bib43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100655_bib44","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","article-title":"Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms","volume":"118","author":"Malcovati","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100655_bib45","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrm3742","article-title":"A day in the life of the spliceosome","volume":"15","author":"Matera","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jbior.2019.100655_bib46","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/blood-2016-10-695981","article-title":"Genomics of chronic neutrophilic leukemia","volume":"129","author":"Maxson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100655_bib47","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","article-title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)","volume":"120","author":"Meggendorfer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100655_bib48","doi-asserted-by":"crossref","first-page":"10004","DOI":"10.1038\/ncomms10004","article-title":"SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment","volume":"6","author":"Mian","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbior.2019.100655_bib49","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3324\/haematol.2012.075325","article-title":"Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome","volume":"98","author":"Mian","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jbior.2019.100655_bib50","doi-asserted-by":"crossref","first-page":"e0201690","DOI":"10.1371\/journal.pone.0201690","article-title":"Strap associates with Csde1 and affects expression of select Csde1-bound transcripts","volume":"13","author":"Moore","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jbior.2019.100655_bib51","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/leu.2016.251","article-title":"Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts","volume":"31","author":"Mupo","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jbior.2019.100655_bib52","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1016\/j.celrep.2018.10.071","article-title":"Constitutive activation of the canonical NF-kappaB pathway leads to bone marrow failure and induction of erythroid signature in hematopoietic stem cells","volume":"25","author":"Nakagawa","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.jbior.2019.100655_bib53","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1158\/0008-5472.CAN-17-3970","article-title":"Spliceosome mutations induce R loop-associated sensitivity to ATR inhibition in myelodysplastic syndromes","volume":"78","author":"Nguyen","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbior.2019.100655_bib54","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.molcel.2017.01.029","article-title":"Functions of replication protein a as a sensor of R loops and a regulator of RNaseH1","volume":"65","author":"Nguyen","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jbior.2019.100655_bib55","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/leu.2012.298","article-title":"The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts","volume":"27","author":"Nikpour","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jbior.2019.100655_bib56","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature08909","article-title":"Expansion of the eukaryotic proteome by alternative splicing","volume":"463","author":"Nilsen","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jbior.2019.100655_bib57","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/acel.12685","article-title":"Sirtuins at the crossroads of stemness, aging, and cancer","volume":"16","author":"O'Callaghan","year":"2017","journal-title":"Aging Cell"},{"key":"10.1016\/j.jbior.2019.100655_bib58","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ccell.2016.08.006","article-title":"Physiologic expression of Sf3b1(K700E) causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation","volume":"30","author":"Obeng","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbior.2019.100655_bib59","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2018-10-844621","article-title":"Genetics of MDS","volume":"133","author":"Ogawa","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100655_bib60","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbior.2019.100655_bib61","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100655_bib62","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1038\/leu.2017.164","article-title":"Genomic determinants of chronic myelomonocytic leukemia","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jbior.2019.100655_bib63","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ajh.23373","article-title":"Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance","volume":"88","author":"Patnaik","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jbior.2019.100655_bib64","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood-2018-04-843771","article-title":"Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes\/pathways and clinical associations","volume":"132","author":"Pellagatti","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100655_bib65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.12515","article-title":"The molecular pathogenesis of the myelodysplastic syndromes","volume":"95","author":"Pellagatti","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.jbior.2019.100655_bib66","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jbior.2016.08.001","article-title":"Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications","volume":"63","author":"Pellagatti","year":"2017","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.jbior.2019.100655_bib67","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/leu.2015.129","article-title":"Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression","volume":"30","author":"Pellagatti","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jbior.2019.100655_bib68","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1093\/nar\/gkt1388","article-title":"A dynamic alternative splicing program regulates gene expression during terminal erythropoiesis","volume":"42","author":"Pimentel","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jbior.2019.100655_bib69","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.canep.2013.05.004","article-title":"Trend (1999-2009) in U.S. death rates from myelodysplastic syndromes: utility of multiple causes of death in surveillance","volume":"37","author":"Polednak","year":"2013","journal-title":"Canc. Epidemiol."},{"key":"10.1016\/j.jbior.2019.100655_bib70","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/onc.2013.120","article-title":"Sorting out functions of sirtuins in cancer","volume":"33","author":"Roth","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.jbior.2019.100655_bib71","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1615\/CritRevOncog.2013010187","article-title":"Sirtuins in hematological aging and malignancy","volume":"18","author":"Roth","year":"2013","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.jbior.2019.100655_bib72","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1182\/blood-2016-10-692400","article-title":"Splicing factor gene mutations in hematologic malignancies","volume":"129","author":"Saez","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100655_bib73","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrg.2015.3","article-title":"RNA mis-splicing in disease","volume":"17","author":"Scotti","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jbior.2019.100655_bib74","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm.4493","article-title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers","volume":"24","author":"Seiler","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.jbior.2019.100655_bib75","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/eji.200324013","article-title":"Caspase-8 and caspase-10 activate NF-kappaB through RIP, NIK and IKKalpha kinases","volume":"33","author":"Shikama","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jbior.2019.100655_bib76","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1038\/s41467-018-06063-x","article-title":"Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia","volume":"9","author":"Shiozawa","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbior.2019.100655_bib77","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ccell.2015.04.008","article-title":"Mutant U2AF1 expression alters hematopoiesis and pre-mRNA splicing in vivo","volume":"27","author":"Shirai","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbior.2019.100655_bib78","doi-asserted-by":"crossref","first-page":"14060","DOI":"10.1038\/ncomms14060","article-title":"Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome","volume":"8","author":"Shirai","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbior.2019.100655_bib79","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41556-019-0314-5","article-title":"U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies","volume":"21","author":"Smith","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.jbior.2019.100655_bib80","series-title":"Phase I dose escalation clinical trial of H3B-8800, a splicing modulator, in patients with advanced myeloid malignancies. HemaSphere (Abstracts of the 24th Congress of the European Hematology Association)","first-page":"467","volume":"3","author":"Steensma","year":"2019"},{"key":"10.1016\/j.jbior.2019.100655_bib81","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.mayocp.2015.04.001","article-title":"Myelodysplastic syndromes: diagnosis and treatment","volume":"90","author":"Steensma","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jbior.2019.100655_bib82","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100655_bib83","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.stem.2018.07.018","article-title":"SIRT1 activation disrupts maintenance of myelodysplastic syndrome stem and progenitor cells by restoring TET2 function","volume":"23","author":"Sun","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jbior.2019.100655_bib84","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","article-title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes","volume":"119","author":"Thol","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100655_bib85","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/nature14512","article-title":"The core spliceosome as target and effector of non-canonical ATM signalling","volume":"523","author":"Tresini","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jbior.2019.100655_bib86","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.cell.2009.02.009","article-title":"The spliceosome: design principles of a dynamic RNP machine","volume":"136","author":"Wahl","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.jbior.2019.100655_bib87","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/leu.2013.58","article-title":"Clonal diversity of recurrently mutated genes in myelodysplastic syndromes","volume":"27","author":"Walter","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jbior.2019.100655_bib88","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1007\/s13277-015-4305-2","article-title":"Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes","volume":"37","author":"Wu","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.jbior.2019.100655_bib89","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1182\/blood-2012-02-412296","article-title":"The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution","volume":"120","author":"Wu","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2019.100655_bib90","doi-asserted-by":"crossref","first-page":"E277","DOI":"10.1002\/ajh.23541","article-title":"Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression","volume":"88","author":"Wu","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jbior.2019.100655_bib91","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1128\/MCB.00288-07","article-title":"Splicing regulator SC35 is essential for genomic stability and cell proliferation during mammalian organogenesis","volume":"27","author":"Xiao","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.jbior.2019.100655_bib92","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.2174\/1381612822666160226132112","article-title":"Impact of splicing factor mutations on pre-mRNA splicing in the myelodysplastic syndromes","volume":"22","author":"Yip","year":"2016","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.jbior.2019.100655_bib93","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1172\/JCI91363","article-title":"The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes","volume":"127","author":"Yip","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jbior.2019.100655_bib94","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jbior.2019.100655_bib95","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/s12185-017-2242-0","article-title":"Splicing factor mutations in MDS RARS and MDS\/MPN-RS-T","volume":"105","author":"Yoshimi","year":"2017","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.jbior.2019.100655_bib96","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1158\/0008-5472.CAN-14-2930","article-title":"A chemical genetics approach for the functional assessment of novel cancer genes","volume":"75","author":"Zhou","year":"2015","journal-title":"Cancer Res."}],"updated-by":[{"DOI":"10.1016\/j.jbior.2021.100856","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000}}],"container-title":["Advances in Biological Regulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492619300764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492619300764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:27:39Z","timestamp":1761949659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212492619300764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":96,"alternative-id":["S2212492619300764"],"URL":"https:\/\/doi.org\/10.1016\/j.jbior.2019.100655","relation":{},"ISSN":["2212-4926"],"issn-type":[{"value":"2212-4926","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Splicing factor mutant myelodysplastic syndromes: Recent advances","name":"articletitle","label":"Article Title"},{"value":"Advances in Biological Regulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbior.2019.100655","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100655"}}